Skip to main content

Advertisement

SpringerLink
Log in

Up-front polytherapy for ALK-positive lung cancer

  • News & Views
  • Published:

From Nature Medicine

View current issue Submit your manuscript

A new study identifies the RAS-MAPK pathway to be an Achilles' heel of EML4-ALK fusion-positive lung cancer and suggests that up-front combination therapy directed against both pathways can achieve sustained suppression of tumor growth.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1: Up-front concurrent inhibition of ALK and MEK leads to sustained tumor growth suppression in EML4-ALK–positive lung cancer.

Marina Corral Spence/Nature Publishing Group

References

  1. Heist, R.S. & Engelman, J.A. Cancer Cell 21, 448.e2 (2012).

    Article  Google Scholar 

  2. Camidge, D.R., Pao, W. & Sequist, L.V. Nat. Rev. Clin. Oncol. 11, 473–481 (2014).

    Article  CAS  Google Scholar 

  3. Katayama, R. et al. Clin. Cancer Res. 21, 2227–2235 (2015).

    Article  CAS  Google Scholar 

  4. Hrustanovic, G. et al. Nat. Med. 21, 1038–1047 (2015).

    Article  CAS  Google Scholar 

  5. Hallberg, B. & Palmer, R.H. Nat. Rev. Cancer 13, 685–700 (2013).

    Article  CAS  Google Scholar 

  6. Tanizaki, J. et al. Br. J. Cancer 106, 763–767 (2012).

    Article  CAS  Google Scholar 

  7. Crystal, A.S. et al. Science 346, 1480–1486 (2014).

    Article  CAS  Google Scholar 

  8. Samatar, A.A. & Poulikakos, P. Nat. Rev. Drug Discov. 13, 928–942 (2014).

    Article  CAS  Google Scholar 

  9. Wilson, F.H. et al. Cancer Cell 27, 397–408 (2015).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Bingying Zhou is in the Department of Pharmacology and the Lineberger Comprehensive Cancer Center at the University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.,

    Bingying Zhou

  2. Adrienne D. Cox is in the Departments of Pharmacology and Radiation Oncology and the Lineberger Comprehensive Cancer Center at the University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.,

    Adrienne D Cox

Authors
  1. Bingying Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Adrienne D Cox
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Adrienne D Cox.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zhou, B., Cox, A. Up-front polytherapy for ALK-positive lung cancer. Nat Med 21, 974–975 (2015). https://doi.org/10.1038/nm.3942

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nm.3942

  • Springer Nature America, Inc.

This article is cited by

Search

Navigation